Coca-Cola Europacific Partners PLC
NASDAQ:CCEPBeverages - Non-Alcoholic
-$0.29 today
- Market cap
- $52.17B
- Beta
- 0.47
- P/E (TTM)
- 19.5
- EPS (TTM)
- $4.32
- Dividend yield
- 2.48%
Volume 1.83M
Average 1.92M
CCEP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Coca-Cola Europacific Partners PLCNASDAQ: CCEP
Research & Development · Q4 FY2025 · quarter ended Dec 2025
Research & development remains negative
Q4 FY2025 research & development was €0, compared with €0 a year earlier.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 0 EUR
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CCEP compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for CCEP, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €0 EUR | — | — | 0.0% | |
| LTM Jul 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | MX$0 MXN | — | — | 0.0% | |
| LTM Jul 2026 | $0 USD | — | — | 0.0% | |
| LTM Aug 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CCEP) | — | — | — | 0.0% | |
Competitors are the stored peer set for CCEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.76B | 17.32B | 18.3B | 20.44B | 20.9B |
| Cost of Revenue | 8.66B | 11.08B | 11.57B | 13.16B | 13.47B |
| Gross Profit | 5.1B | 6.24B | 6.73B | 7.28B | 7.44B |
| Gross Margin | 37.1% | 36.0% | 36.8% | 35.6% | 35.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 3.39B | 4.09B | 4.39B | 4.68B | 4.65B |
| Operating Expenses | 3.59B | 4.16B | 4.39B | 5.15B | 4.64B |
| Depreciation & Amortization | 722M | 772M | 781M | 633M | 637M |
| EBITDA | 2.44B | 2.93B | 3.23B | 3.24B | 3.43B |
| EBITDA Margin | 17.7% | 16.9% | 17.6% | 15.9% | 16.4% |
| Operating Income | 1.52B | 2.09B | 2.34B | 2.13B | 2.79B |
| Operating Margin | 11.0% | 12.0% | 12.8% | 10.4% | 13.4% |
| Interest Income | 44.83M | 17M | 114M | 55M | 98.93M |
| Interest Expense | 95.91M | 131M | 162M | 242M | 293.92M |
| Other Income / Expenses | (134M) | (129M) | (136M) | (196M) | (224M) |
| Income Before Tax | 1.38B | 1.96B | 2.2B | 1.94B | 2.57B |
| Pre-Tax Margin | 10.0% | 11.3% | 12.0% | 9.5% | 12.3% |
| Income Tax Expense | 394M | 436M | 534M | 492M | 590M |
| Net Income | 982M | 1.51B | 1.67B | 1.42B | 1.94B |
| Net Margin | 7.1% | 8.7% | 9.1% | 6.9% | 9.3% |
| EPS (Basic) | 2.15 | 3.30 | 3.63 | 3.08 | 4.09 |
| EPS (Diluted) | 2.15 | 3.29 | 3.64 | 3.08 | 4.09 |
| Weighted Avg Shares | 456M | 457M | 459M | 460.39M | 456M |
| Weighted Avg Shares (Diluted) | 457M | 458M | 459M | 461M | 456M |
Coca-Cola Europacific Partners PLC
NASDAQ:CCEP
Intrinsic Alpha fair value
Locked
Current Price
$118.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.